{"id":"https://openalex.org/W2897274926","doi":"https://doi.org/10.2147/cpaa.s169505","title":"Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects","display_name":"Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects","publication_year":2018,"publication_date":"2018-10-01","ids":{"openalex":"https://openalex.org/W2897274926","doi":"https://doi.org/10.2147/cpaa.s169505","mag":"2897274926","pmid":"https://pubmed.ncbi.nlm.nih.gov/30498375","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6207247"},"language":"en","primary_location":{"id":"doi:10.2147/cpaa.s169505","doi":"https://doi.org/10.2147/cpaa.s169505","is_oa":true,"landing_page_url":"https://doi.org/10.2147/cpaa.s169505","pdf_url":"https://www.dovepress.com/getfile.php?fileID=45576","source":{"id":"https://openalex.org/S4210204454","display_name":"Clinical Pharmacology Advances and Applications","issn_l":"1179-1438","issn":["1179-1438"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology: Advances and Applications","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=45576","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103820467","display_name":"Charles E. Frost","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Charles Frost","raw_affiliation_strings":["Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049683780","display_name":"Andrew Shenker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Shenker","raw_affiliation_strings":["Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059074751","display_name":"Stanford S. Jhee","orcid":"https://orcid.org/0000-0002-0784-6522","observed_orcids":["https://orcid.org/0000-0002-0784-6522"]},"institutions":[{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stanford Jhee","raw_affiliation_strings":["PAREXEL International Early Phase, Glendale, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PAREXEL International Early Phase, Glendale, CA, USA","institution_ids":["https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101847949","display_name":"Zhigang Yu","orcid":"https://orcid.org/0000-0002-3093-4491","observed_orcids":["https://orcid.org/0000-0002-3093-4491","https://orcid.org/0009-0002-2713-8686"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhigang Yu","raw_affiliation_strings":["Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065566858","display_name":"Jessie J.J. Wang","orcid":"https://orcid.org/0000-0002-4539-3771","observed_orcids":["https://orcid.org/0000-0002-4539-3771"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessie Wang","raw_affiliation_strings":["Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076636193","display_name":"Alexander Bragat","orcid":"https://orcid.org/0000-0002-0993-9896","observed_orcids":["https://orcid.org/0000-0002-0993-9896"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander Bragat","raw_affiliation_strings":["Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;"],"raw_orcid":"https://orcid.org/0000-0002-0993-9896","affiliations":[{"raw_affiliation_string":"Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039947213","display_name":"Janice M. Pursley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janice Pursley","raw_affiliation_strings":["Analytical and Bioanalytical Development, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analytical and Bioanalytical Development, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087648612","display_name":"Frank P. LaCreta","orcid":"https://orcid.org/0000-0001-8266-5927","observed_orcids":["https://orcid.org/0000-0001-8266-5927"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank LaCreta","raw_affiliation_strings":["Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;"],"raw_orcid":"https://orcid.org/0000-0001-8266-5927","affiliations":[{"raw_affiliation_string":"Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA, charles.frost@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"exploratory Clinical and Translational research, Bristol-Myers squibb, Princeton, nJ, UsA;","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5103820467"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":2320,"currency":"USD","value_usd":2320},"apc_paid":{"value":2320,"currency":"USD","value_usd":2320},"fwci":0.9116,"has_fulltext":true,"cited_by_count":24,"citation_normalized_percentile":{"value":0.73766692,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"Volume 10","issue":null,"first_page":"153","last_page":"163"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.6083999872207642,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.6083999872207642,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.12380000203847885,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.11069999635219574,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9520000219345093},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":1.0},{"id":"https://openalex.org/keywords/single-dose-administration","display_name":"single-dose administration","score":0.7639999985694885},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.8059999942779541},{"id":"https://openalex.org/keywords/anticoagulation","display_name":"anticoagulation","score":0.675000011920929},{"id":"https://openalex.org/keywords/international-normalized-ratio","display_name":"international normalized ratio","score":0.6420000195503235},{"id":"https://openalex.org/keywords/activated-partial-thromboplastin-time","display_name":"activated partial thromboplastin time","score":0.9470000267028809},{"id":"https://openalex.org/keywords/renal-clearance","display_name":"renal clearance","score":0.8450000286102295},{"id":"https://openalex.org/keywords/ethnic-differences","display_name":"ethnic differences","score":0.6340000033378601}],"concepts":[{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.9321094751358032},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7807914614677429},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.776719868183136},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7576804161071777},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.7155303955078125},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5865193605422974},{"id":"https://openalex.org/C2778261982","wikidata":"https://www.wikidata.org/wiki/Q1755136","display_name":"Partial thromboplastin time","level":3,"score":0.5594877004623413},{"id":"https://openalex.org/C2780434524","wikidata":"https://www.wikidata.org/wiki/Q1144385","display_name":"Prothrombin time","level":2,"score":0.4796469807624817},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4361491799354553},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36636126041412354},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3648531436920166},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.15274754166603088},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.09651392698287964},{"id":"https://openalex.org/C2778382381","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Coagulation","level":2,"score":0.08483767509460449},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.0}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.2147/cpaa.s169505","doi":"https://doi.org/10.2147/cpaa.s169505","is_oa":true,"landing_page_url":"https://doi.org/10.2147/cpaa.s169505","pdf_url":"https://www.dovepress.com/getfile.php?fileID=45576","source":{"id":"https://openalex.org/S4210204454","display_name":"Clinical Pharmacology Advances and Applications","issn_l":"1179-1438","issn":["1179-1438"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology: Advances and Applications","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5236173","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6207247","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmid:30498375","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30498375","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology : advances and applications","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6207247","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6207247/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:108edafcc5d147b8b447e1bf8b6c79f0","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/108edafcc5d147b8b447e1bf8b6c79f0","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical Pharmacology: Advances and Applications, Vol Volume 10, Pp 153-163 (2018)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/41705","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/evaluation-of-the-single-dose-pharmacokinetics-and-pharmacodynamics-of-peer-reviewed-article-CPAA","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/cpaa.s169505","doi":"https://doi.org/10.2147/cpaa.s169505","is_oa":true,"landing_page_url":"https://doi.org/10.2147/cpaa.s169505","pdf_url":"https://www.dovepress.com/getfile.php?fileID=45576","source":{"id":"https://openalex.org/S4210204454","display_name":"Clinical Pharmacology Advances and Applications","issn_l":"1179-1438","issn":["1179-1438"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology: Advances and Applications","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2897274926.pdf","grobid_xml":"https://content.openalex.org/works/W2897274926.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W1507763452","https://openalex.org/W1568662837","https://openalex.org/W1744228080","https://openalex.org/W1878559559","https://openalex.org/W1973598884","https://openalex.org/W1979937973","https://openalex.org/W2017600141","https://openalex.org/W2026517280","https://openalex.org/W2032692864","https://openalex.org/W2038203531","https://openalex.org/W2073584640","https://openalex.org/W2074026346","https://openalex.org/W2107361996","https://openalex.org/W2119768870","https://openalex.org/W2131569638","https://openalex.org/W2162508946","https://openalex.org/W2166402206","https://openalex.org/W2313548138","https://openalex.org/W2333514251","https://openalex.org/W2617973506","https://openalex.org/W2892665712"],"related_works":["https://openalex.org/W2032692864","https://openalex.org/W2073584640","https://openalex.org/W1568662837","https://openalex.org/W1507763452","https://openalex.org/W3191106360","https://openalex.org/W2073493628","https://openalex.org/W2946652117","https://openalex.org/W3084231761","https://openalex.org/W1824996723","https://openalex.org/W2617973506"],"abstract_inverted_index":{"Purpose:":[0],"This":[1],"double-blind,":[2],"placebo-controlled,":[3],"intra-subject,":[4],"dose-escalation":[5],"study":[6],"assessed":[7],"single-dose":[8],"safety,":[9,261],"pharmacokinetics,":[10,262],"and":[11,18,22,28,38,56,90,95,121,160,168,171,177,182,199,201,219,224,234,239],"pharmacodynamics":[12],"of":[13,50,76,108,115,197,203,210],"apixaban":[14,52,77,109,116,211,244],"in":[15,158,180,222,227,237,257],"healthy":[16,25,30],"Japanese":[17,27,159,181,223,238,258],"Caucasian":[19,32,161,183,225,240],"subjects.":[20,126,162],"Subjects":[21],"methods:":[23],"Sixteen":[24],"male":[26,31],"sixteen":[29],"subjects,":[33,184],"matched":[34,60],"for":[35,73,105,255],"age,":[36],"weight,":[37],"smoking":[39],"status":[40],"were":[41,63,71,103,119,188,217],"randomized":[42],"to":[43,134,155],"receive":[44],"four":[45],"sequential":[46],"single":[47,113,208],"oral":[48],"doses":[49,114,209],"either":[51],"(2.5,":[53],"10,":[54],"25,":[55],"50":[57],"mg)":[58],"or":[59],"placebo.":[61],"Doses":[62],"separated":[64],"by":[65,124],"a":[66,213,249],"\u22655-day":[67],"washout.":[68],"Blood":[69],"samples":[70,102],"collected":[72,104],"the":[74,106,130,172],"determination":[75],"plasma":[78],"concentration,":[79],"clotting":[80],"times":[81],"(international":[82],"normalized":[83],"ratio":[84],"[INR],":[85],"activated":[86],"partial":[87],"thromboplastin":[88],"time,":[89],"modified":[91],"prothrombin":[92],"time":[93],"[mPT]),":[94],"ex":[96],"vivo":[97],"thrombin":[98],"generation":[99],"(TG).":[100],"Urine":[101],"analysis":[107],"concentration.":[110],"Results:":[111],"Ascending":[112,207],"2.5\u201350":[117],"mg":[118],"safe":[120,218],"well":[122,220],"tolerated":[123,221],"all":[125],"Apixaban":[127,137],"exposure":[128],"increased":[129],"dose":[131,215,251],"proportionally":[132],"up":[133],"10":[135],"mg.":[136],"reached":[138],"maximum":[139],"concentrations":[140],"(":[141],"C":[142,150],"max":[143,151],")":[144],"3\u20134":[145],"h":[146,170],"postdose,":[147],"with":[148,193,252],"mean":[149,164],"ranging":[152],"from":[153],"52.5\u2013485.0":[154],"44.8\u2013494.3":[156],"ng/mL":[157],"The":[163,230],"half-life":[165],"was":[166,175],"~8":[167],"~13":[169],"renal":[173],"clearance":[174],"1.1":[176],"0.8":[178],"L/h":[179],"respectively.":[185],"Pharmacodynamic":[186],"assessments":[187],"similar":[189],"between":[190,232],"ethnic":[191],"groups,":[192],"comparable":[194],"dose-related":[195],"prolongation":[196],"INR":[198],"mPT":[200],"inhibition":[202],"TG.":[204],"Conclusion":[205],":":[206],"over":[212],"20-fold":[214],"range":[216],"subjects":[226,241],"this":[228],"study.":[229],"consistency":[231],"pharmacokinetic":[233],"pharmacodynamic":[235],"measures":[236],"indicates":[242],"that":[243],"may":[245],"be":[246],"administered":[247],"as":[248],"fixed":[250],"no":[253],"need":[254],"adjustment":[256],"patients.":[259],"Keywords:":[260],"pharmacodynamics,":[263],"Japanese,":[264],"apixaban,":[265],"anticoagulation,":[266],"Asian,":[267],"novel,":[268],"Eliquis":[269]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2018-10-26T00:00:00"}